Phase 2 Myeloma Trial, Recruiting NCT07106671 Sponsor: Institute of Hematology & Blood Diseases Hospital, China Condition: Myeloma
Back to Myeloma

Phase 2 Myeloma Trial, Recruiting

NCT07106671
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to be informed about the trial and sign a consent form agreeing to take part voluntarily.
  • You are 18 years of age or older.
  • You have been diagnosed with multiple myeloma (a type of blood cancer) using standard international diagnostic guidelines.
  • You have experienced a reaction called CRS (cytokine release syndrome) and/or a brain-related side effect called ICANS after receiving CAR-T cell therapy (a type of immune cell treatment).

Who may not be able to join:

  • Your kidneys are not filtering blood well enough (low kidney function, confirm with trial site).
  • Your blood counts are too low at the time of screening — this includes low platelets (which help blood clot), low white blood cells (which fight infection), or low red blood cells (which carry oxygen).
  • Your liver is not working well enough, based on blood test results showing certain liver-related levels are too high.
  • You have serious heart problems, such as severe heart failure, uncontrolled chest pain, irregular heartbeat, very high blood pressure, a heart attack within the last 6 months, or a prior stroke that has left lasting effects.
  • You have certain other serious health conditions, including active infections, active hepatitis B or C, HIV, uncontrolled diabetes, severe lung disease, or significant liver scarring (cirrhosis).
  • You are known to have a bad reaction or allergy to the drug Siltuximab.
  • The cancer has spread to your brain or spinal cord (central nervous system involvement).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-022-23909171

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Registry
ClinicalTrials.gov
Start date
10 August 2025
Est. completion
1 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete CRS resolution rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov